This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): cabotegravir, S-265744 LAP, S/GSK1265744 LAP, GSK744 LA
Description: S-265744 LAP is an long acting parenteral injection formulation of GSK 1265744, and also acts as an HIV integrase inhibitor.
Shionogi and GSK
In July 2001, Shionogi and GlaxoSmithKline announced a plan to form a joint venture to develop and market several drugs in clinical trials, including new agents to fight against HIV and neurological disorders.
Under the terms of a letter of intent, Shionogi and GSK plan to create a joint venture (JV) that will initially have exclusive rights to develop and commercialise four compounds contributed by Shionogi and one by GSK. The JV is expected to operate in the US and in major European markets. GSK will have exclusive marketing rights in countries where the JV does not operate, excluding Japan and Taiwan, where Shionogi will retain exclusive marketing rights to all Shionogi compounds. GSK will also have co-promotion rights in those JV markets where GSK's capabilities could enhance commercialisation efforts.
GSK and Shionogi will make milestone payments to the JV tied to the progression of the compounds contributed by the partner company. Both...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd. Pfizer Inc.
Additional information available to subscribers only: